
Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).

Your AI-Trained Oncology Knowledge Connection!


Published: April 28th 2017 | Updated: